摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-dibenzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol | 105202-62-8

中文名称
——
中文别名
——
英文名称
3,5-dibenzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol
英文别名
3,5-dibenzyl-6H-triazolo[4,5-d]pyrimidin-7-one
3,5-dibenzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol化学式
CAS
105202-62-8
化学式
C18H15N5O
mdl
MFCD06618012
分子量
317.35
InChiKey
BHRBEXROVFSTQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    72.2
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    3,5-dibenzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-olN,N-二乙基苯胺三氯氧磷 作用下, 以 乙醇 为溶剂, 反应 16.0h, 生成 3,5-Dibenzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ylamine
    参考文献:
    名称:
    2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies
    摘要:
    A number of N-6-(N-arylcarbamoyl)-2-substituted-9-benzyl-8-azaadenines, obtained by a modification of the synthetic scheme used to prepare selective A(1) ligands, by only three or two steps, are described. At first we prepared a series of 2-phenyl-9-benzyl-8-azaadenines having as N-6 substituent a variously substituted N-phenylcarbamoyl group. Some of these derivatives demonstrated good affinity towards the A(3) subtype but low selectivity. Compounds having p-CF3, p-F and p-OCH3, as substituents on the phenylcarbamoyl group were selected as lead compounds for the second part of this study. Without modifying the N-6 substituent, which would assure A(3) affinity, we varied the 9 and 2 positions on these molecules to enhance selectivity. Some compounds having a p-methyl group on the 2-phenyl substituent showed a very good affinity and selectivity for the A(3) subtype, revealing the first class of A(3) adenosine receptor selective antagonists with a bicyclic structure strictly correlated to the adenine nucleus. The molecular modelling work, carried out using the DOCK program, supplied two models which may be useful for a better understanding of the binding modes. Both models highlighted the preferred interacting tautomeric forms of the antagonists for human A(1) and A(3) receptors. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2005.04.063
  • 作为产物:
    描述:
    苄基叠氮sodium ethanolate 作用下, 以 乙醇 为溶剂, 反应 9.0h, 生成 3,5-dibenzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol
    参考文献:
    名称:
    2,9-二取代的8-氮杂嘌呤-6-(3,5-二取代的7-羟基-3 H -1,2,3-三唑并[4,5- d ]嘧啶的简便“一锅”合成)
    摘要:
    利用苄基叠氮化物,氰基乙酰胺,脂族或芳族羧酸的乙酯或甲酯和乙醇钠合成了一系列标题化合物。
    DOI:
    10.1002/jhet.5570220628
点击查看最新优质反应信息

文献信息

  • A facile “one pot” synthesis of 2,9-disubstituted 8-azapurin-6-ones (3,5-disubstituted 7-hydroxy-3<i>H</i>-1,2,3-triazolo[4,5-<i>d</i>]pyrimidines)
    作者:Pier Luigi Barili、Giuliana Biagi、Oreste Livi、Valerio Scartoni
    DOI:10.1002/jhet.5570220628
    日期:1985.11
    A series of title compounds have been synthesized by utilising benzylazide, cyanoacetamide, ethyl or methyl esters of aliphatic or aromatic carboxylic acids and sodium ethoxide as catalyst.
    利用苄基叠氮化物,氰基乙酰胺,脂族或芳族羧酸的乙酯或甲酯和乙醇钠合成了一系列标题化合物。
  • BARILI, P. L.;BIAGI, G.;LIVI, O.;SCARTONI, V., J. HETEROCYCL. CHEM., 1985, 22, N 6, 1607-1609
    作者:BARILI, P. L.、BIAGI, G.、LIVI, O.、SCARTONI, V.
    DOI:——
    日期:——
  • 2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies
    作者:Giuliana Biagi、Anna Maria Bianucci、Alessio Coi、Barbara Costa、Laura Fabbrini、Irene Giorgi、Oreste Livi、Iolanda Micco、Federica Pacchini、Edoardo Santini、Michele Leonardi、Fatena Ahmad Nofal、Oreste LeRoy Salerni、Valerio Scartoni
    DOI:10.1016/j.bmc.2005.04.063
    日期:2005.8
    A number of N-6-(N-arylcarbamoyl)-2-substituted-9-benzyl-8-azaadenines, obtained by a modification of the synthetic scheme used to prepare selective A(1) ligands, by only three or two steps, are described. At first we prepared a series of 2-phenyl-9-benzyl-8-azaadenines having as N-6 substituent a variously substituted N-phenylcarbamoyl group. Some of these derivatives demonstrated good affinity towards the A(3) subtype but low selectivity. Compounds having p-CF3, p-F and p-OCH3, as substituents on the phenylcarbamoyl group were selected as lead compounds for the second part of this study. Without modifying the N-6 substituent, which would assure A(3) affinity, we varied the 9 and 2 positions on these molecules to enhance selectivity. Some compounds having a p-methyl group on the 2-phenyl substituent showed a very good affinity and selectivity for the A(3) subtype, revealing the first class of A(3) adenosine receptor selective antagonists with a bicyclic structure strictly correlated to the adenine nucleus. The molecular modelling work, carried out using the DOCK program, supplied two models which may be useful for a better understanding of the binding modes. Both models highlighted the preferred interacting tautomeric forms of the antagonists for human A(1) and A(3) receptors. (c) 2005 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

阿扎次黄嘌呤 钠2-氨基-6-甲基-[1,2,4]三唑并[1,5-a]嘧啶-5-醇 替格瑞洛 曲匹地尔 异亚丙基替卡格雷 布美地尔 唑嘧菌胺 唑嘧磺草胺 去羟基乙氧基替格雷洛 化合物 T15173 v-三唑并[4,5-d]嘧啶,(3H),3-环戊基-7-偏基硫代- [[[3-(4,7-二氢-7-氧代-1H-1,2,3-三唑并[4,5-d]嘧啶-5-基)-4-丙氧基苯基]氨基]亚甲基]丙二酸二乙酯 [1,2,4]噻唑并[1,5-c]嘧啶-5(6h)-酮 [1,2,4]三氮唑并[1,5-A]嘧啶-2-胺 [1,2,4]三唑并[3,4-f]嘧啶 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸甲酯 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸 [1,2,4]三唑[1,5,A]嘧啶-7-氨基 [(1R,3S)-3-(5-氨基-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 [(1R,3S)-3-(5,7-二氨基-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 N-甲基-1H-1,2,3-三唑并[4,5-d]嘧啶-7-胺 N-(4'-氟丁酰苯)-4-(4-氯苯基)吡啶正离子 N-(2,6-二氯苯基)-5,7-二甲基[1,2,4]三唑并[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲苯基)-5,7-二甲氧基-[1,2,4]三唑[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲基苯基)-5,7-二氯-1,2,4-三唑并[1,5-a]吡啶-2-磺酰胺 N-(1,5,6,7-四氢-3,6-二甲基-5,7-二氧代-1,2,4-三唑并[4,3-c]嘧啶-8-基)-乙酰胺 EED抑制剂(EEDINHIBITOR-1) 9H-7,8-二氢-(1,2,3)三唑并(4',5'-4,5)嘧啶并(6,1-b)(1,3)噻嗪-5(3H)-酮 9-乙基-2,4,7,8,9-五氮杂双环[4.3.0]壬-1,3,5,7-四烯-3,5-二胺 8-甲氧基-3-甲基-[1,2,4]三唑并[4,3-C]嘧啶 8-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 8-溴-[1,2,4]三唑并[4,3-c]嘧啶 8-溴-5-(甲硫基)[1,2,4]三唑并[4,3-c]嘧啶 8-氮鸟嘌呤 8-氮杂黄嘌呤 8-氮杂腺嘌呤 8-氮杂-2,6-二氨基嘌呤硫酸盐 8-乙氧基-5-甲氧基[1,2,4]三唑并[1,5-c]嘧啶-2-胺 8-乙基-4-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 7H-[1,2,3]三唑并[4,5-d]嘧啶 7-(2-呋喃基)[1,2,4]三唑并[1,5-a]嘧啶-2-基胺 7-羟基-5-甲基-2(甲硫基)-1,2,4-三唑并[1,5-a]嘧啶-6-羧酸乙酯 7-羟基-5-甲基-1,3,4-三氮吲哚利嗪 7-甲基[1,2,4]三唑并[4,3-A]嘧啶-3-羧酸 7-甲基[1,2,4]三唑并[1,5-a]嘧啶-5-醇 7-甲基-[1,2,4]噻唑并[4,3-c]嘧啶 7-甲基-8-丙基-[1,2,4]噻唑并[1,5-c]嘧啶 7-环丙基[1,2,4]三唑[1,5-a]嘧啶-2-胺 7-氯-[1,2,4]噻唑并[1,5-c]嘧啶 7-氯-[1,2,4]噻唑并[1,5-a]嘧啶